← Back to Search

Other

Ablative Therapy for Prostate Cancer

Phase 2
Recruiting
Led By Xiaosong Meng, MD, PhD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years post-treatment
Awards & highlights

Study Summary

This trial will study new ways to treat localized prostate cancer while measuring the impacts on quality of life.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in erectile function as measured by International Index of Erectile Function (IIEF-5) score questionnaire (primary setting)
Change in erectile function as measured by International Index of Erectile Function (IIEF-5) score questionnaire (salvage setting)
Change in urinary function as measured by International Prostate Symptom Score (IPSS) questionnaire (primary setting)
+5 more
Secondary outcome measures
Number of participants undergoing combined treatment of the transitional zone (TZ ) due to bladder outlet obstruction caused by Benign prostatic hyperplasia (BPH)
Number of participants with adverse events or long-term complications (primary setting)
Number of participants with adverse events or long-term complications (salvage setting)
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ablative TherapyExperimental Treatment1 Intervention
Ablative therapies will be delivered via a whole gland or focal approach by systems including cryoablation (CA), irreversible electroporation (IRE), high intensity focused ultrasound (HIFU), and the novel MRI-guided transurethral ultrasound ablation (TULSA) procedure based on investigator discretion

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,047 Previous Clinical Trials
1,053,574 Total Patients Enrolled
16 Trials studying Prostate Cancer
1,935 Patients Enrolled for Prostate Cancer
Xiaosong Meng, MD, PhDPrincipal InvestigatorUT Southwestern Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Outcomes of Focal Ablation for Prostate Cancer
Xiaosong Meng 2023. "Outcomes of Focal Ablation for Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05478694.
~145 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top